New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Connor Iapoce is the assistant managing editor for 

joining the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to the movies, and playing with his cat, Squish. You can reach him at 

A subgroup analysis of a Phase 4, open-label, single-arm, multicenter study demonstrated the benefit of cyclosporine (CsA) ophthalmic solution 0.09% (CEQUA) for patients with 

 uncontrolled on CsA ophthalmic emulsion 0.05% (Restasis).

American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

, these data showed CsA 0.09% led to a statistical improvement in corneal fluorescein staining (CFS) and modified Symptom Assessment in Dry Eye (mSANDE) scores from Weeks 4 to 12, irrespective of age or gender.

“Males showed more robust improvement in mSANDE scores than females; statistical comparisons between subgroups were not performed,” wrote the investigative team, led by Richard Adler, MD, director of ophthalmology at Azman Eye Care Specialists. “CsA 0.09% was generally well tolerated, with more reported adverse events of mild severity.”

Characterized by the loss of tear film homeostasis, hyperosmolarity, and tear film instability, DED perpetuates ocular surface inflammation and damage, particularly in females and older individuals. The US Food and Drug Administration (FDA) approved the anti-inflammatory agents, CsA 0.09% and CsA 0.5%, to increase tear production in individuals with DED.

This study evaluated the age- and sex-associated differences for the efficacy of CsA 0.09% in patients with DED still symptomatic or exhibiting signs of disease on current CsA 0.05% treatment for more than 3 months. Key inclusion criteria included a total CFS score ≥6 (range, 0-20) or ≥2 in an individual zone (range, 0–4) in 1 eye and a mSANDE global symptom score ≥40 (range, 0-100).

Enrolled individuals applied a single drop of CsA 0.09% per eye twice daily over 12 weeks. Adler and colleagues assessed CFS and mSANDE questionnaire scores at baseline and Weeks 4, 8, and 12, or those who discontinued the study early—safety analysis included monitoring for and reporting adverse events at each study visit. An age- and sex-based subgroup analysis was performed for each efficacy and safety outcome.

Overall, the study enrolled 124 patients, including 109 females, with a median age of 68 years. Most patients were White (88%) and not Hispanic or Latino (86%). At baseline, the mean total CFS scores were 6.8 and 4.7 for those above and below the median age, respectively. The respective scores were 4.2 and 5.9 for males and females.

The mean baseline mSANDE scores were 63.2 and 70.5 for those above and below the median age, respectively, and 75.8 and 65.9 for males and females, respectively. The analysis found the mean changes from baseline in CFS and mSANDE scores significant at Weeks 4, 8, and 12, irrespective of age (

“Twice-daily CsA 0.09% demonstrated significant improvement from baseline in total CFS and mSANDE scores at Weeks 4, 8, and 12 of treatment in patients with DED inadequately controlled on CsA 0.0%, regardless of age or sex,” Adler and colleagues wrote.

Adler R, Johnston K, Hessen M, Nichols KK et al. Cyclosporine Solution 0.09% in Patients with Dry Eye Uncontrolled on Cyclosporine Emulsion 0.05%: A Subgroup Analysis. Poster presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.


Articles

A Phase 4 study demonstrated that cyclosporine ophthalmic solution 0.09% (CEQUA) significantly improved outcomes for patients with dry eye disease (DED) inadequately managed on cyclosporine emulsion 0.05% (Restasis). The study, presented at the 2025 ASCRS Annual Meeting, showed improvements in corneal fluorescein staining (CFS) and modified Symptom Assessment in Dry Eye (mSANDE) scores from Weeks 4 to 12, regardless of age or gender. Males exhibited more robust mSANDE score improvements. The treatment was generally well tolerated, with mild adverse events reported.

Cyclosporine 0.09% significantly improves dry eye symptoms in patients inadequately treated with lower concentrations, enhancing quality of life.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Cyclosporine Solution 0.09% Boosts Outcomes in Uncontrolled Dry Eye

Christina Y. Weng, MD, MBA, is a professor and the Alice R. McPherson Retina Research Foundation Chair in Ophthalmology at Baylor College of Medicine.

Implications of Gene Therapy in Retina, With Christina Y. Weng, MD

In a field marked by rapid innovation, gene therapy is emerging as one of the most promising advances in 

, Christina Y. Weng, MD, MBA, a professor and the Alice R. McPherson Retina Research Foundation Chair in Ophthalmology at Baylor College of Medicine, offered perspective on the transformative potential of these therapies and what they could mean for both patients and providers.

Weng outlined how these gene therapies have the potential to raise the bar for treatment durability to new levels, highlighting three key benefits these therapies could offer: more consistent dosing, fewer injections, and greater overall efficiency in disease management.

“The first one is that we know that most patients are under-treated with anti-VEGF in the real world, and consequently, they suffer from suboptimal visual outcomes,” Weng told 

. “By providing constant dosing of anti-VEGF, gene therapy might help counteract this challenge.”

Weng also emphasized the value of steady dosing, noting that current treatment methods center on bolus dosing, which often causes recurrent anatomic fluctuations and could negatively impact outcomes. Gene therapy could provide a steadier level of dosing, which could render benefits not yet fully realized, as well as lead to fewer burdensome injections.

“Those injections are not only associated with psychological burden, financial burden, but there's also substantial socioeconomic costs,” Weng told 

. “Many of these patients come in each time, bringing in an accompaniment or arranging transportation, etc. All those things can also be reduced with the reduced treatment burden that gene therapy might bring.”

As several gene therapy programs reach late-stage trials, Weng is closely watching the results to see if efficacy signals seen in earlier trials are replicated with larger cohorts. She cited the importance of safety, with reported issues like intraocular inflammation and pigmentary changes becoming important factors in regulatory and clinical decision-making.

“All of the programs I've mentioned have found their gene therapy candidates to be well tolerated, but many have also been associated with adverse events such as intraocular inflammation, pigmentary changes, and episcleritis,” Weng told 

. “The Phase 3 studies will provide important insights on safety, and they're also going to pressure test some of the prophylactic strategies being evaluated.

Looking ahead, Weng noted gene therapy could drive a paradigm shift in disease management,” particularly when paired with advances like home optical coherence tomography (OCT). However, questions remain about how these new options will fit into treatment algorithms.

“We’ve entered the era of gene therapy, not just for rare diseases, but also for some of our most common,” Weng told 

. “Several programs are in late stages, and those results will be key in providing safety and efficacy data that will determine the viability of these gene therapy candidates. If they do emerge on the market, they have the potential of significantly reducing treatment burden and potentially improving visual outcomes for our patients.”

Weng reports relevant disclosures with Alcon, AbbVie, Apellis, Astellas/Iveric Bio, Genentech, Regeneron, and others.

Weng CY. The Current State of Gene Therapy for Retinal Diseases. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Videos

Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

Geographic Atrophy

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

An analysis of results from the Coronary Artery Risk Development in Young Adults (CARDIA) study has indicated that both 

 improvement in young adults and better cardiovascular health in middle age were independently associated with lower midlife risk of 

Investigators utilized Life’s Essential 8 (LE8), an updated version of the quantitative metric for monitoring and measuring CVH created by the American Heart Association (AHA) in 2010. The original consisted of seven core features: healthy diet, participation in physical activity, nicotine avoidance, healthy weight, and healthy blood pressure, blood lipids, and blood glucose. The eighth factor, healthy sleep, was added in 2022.

“Most literature on the association between cardiovascular health (CVH) and incident cardiovascular disease (CVD) and mortality has relied on single midlife measurements,” wrote James Walker, BA, department of preventative medicine, Northwestern University Feinberg School of Medicine, and colleagues. “Understanding how cumulative CVH over time influences later-life CVD and mortality may aid early prevention.”

The CARDIA study, a longitudinal, community-based cohort study that ran from 1985-2020, involved 5115 participants between 18-30 years. Walker and colleagues quantified CVH from these data according to the AHA’s LE8 score, with each measure scored on a scale of 0-100 points. Overall LE8 score was calculated as the unweighted mean of all 8 metrics.

Investigators established a primary outcome of CVD incident through 2022, with a secondary outcome of all-cause mortality. 45 years was marked as the start of outcome follow-up time. Of the original 5115 participants, 4832 had the necessary follow-up data for inclusion in the study – those who had experienced CVD events or died before age 45 were also excluded.

Participants were divided into 4 quartiles based on cumulative LE8 score: the team assessed the relationship between LE8 scores before and after age 45 using multivariable Cox proportional hazards regression models. Outcomes were fitted into the quartile model as a categorical variable (percent by quartile: 0-25

) and as a continuous variable (per 20 points higher LE8 point x years). A model was fitted with the covariates of cumulative LE8 score and a single LE8 score measure at 45 years to assess the relationship between them.

The 4832 included CARDIA participants, of which 2690 (55.7%) were female, had a mean cumulative LE8 score from 18-45 years of 2018.8 (95.0) point x years. The difference between mean Q1 and Q4 cumulative LE8 scores was marked as 626 point x years. Q4 participants exhibited the most favorable CVH health metric levels, including BMI, blood pressure, blood lipid levels, nicotine exposure, serum glucose value, etc.) followed sequentially by Q3, 2, and 1.

Investigators also noted that, during the 14.2 years of follow-up, 285 CVD deaths and 323 deaths from all causes occurred. Participants with the highest quartile of cumulative LE8 score had the least mortality and CVD events during follow-up; each lower quartile exhibited a higher risk of developing mortality or CVD.

Compared with the lowest quartile, 2, 3, and 4 all had significantly lower hazard ratios (HRs) for CVD (Q2 HR, 0.44; 95% CI, .32-.61; Q3 HR, .26; 95% CI, .18-38; Q4 HR, .12; 95% CI, .07-.21) and mortality (Q2 HR, .51; 95% CI, .36-.71; Q3 HR, .38; 95% CI, .26-.55; Q4 HR, .29; 95% CI, .18-.45) after age 45. Cumulative and improvement of LE8 scores from 18-45 years also associated significantly with lower CVD risk.

The team notes that these data indicate a greater cumulative time at higher CVH during young adulthood correlates with lower risk of CVD development in later years.

“Point x years and points up could be useful ways to communicate and promote CVH to young adult patients,” Walker and colleagues wrote. “Given the recent promising research on harnessing gamification to encourage patients to change their health behaviors, further research could examine the potential for using point x years and points up in the LE8 paradigm to improve young adult CVH.”

Walker J, Won D, Guo J, et al. Cumulative Life’s Essential 8 Scores and Cardiovascular Disease Risk. JAMA Cardiol. Published online April 23, 2025. doi:10.1001/jamacardio.2025.0630

Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s essential 8: Updating and enhancing the American Heart Association’s construct of Cardiovascular Health: A presidential advisory from the American Heart Association. 

. 2022;146(5). doi:10.1161/cir.0000000000001078

The CARDIA study highlights the importance of maintaining cardiovascular health (CVH) from young adulthood to middle age to reduce midlife cardiovascular disease (CVD) risk. Utilizing the American Heart Association's Life’s Essential 8 (LE8) metric, which includes healthy sleep, the study found that higher cumulative LE8 scores correlate with lower CVD and mortality risks. Participants with better CVH metrics, such as BMI and blood pressure, had significantly lower hazard ratios for CVD and mortality. The study suggests using gamification to promote CVH improvements in young adults.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Cardiovascular Health in Youth Linked to Lower Disease Risk in Adulthood

Interim safety and efficacy data from the first-in-human study of the SpyGlass Drug Delivery Platform showed key improvements in vision and intraocular pressure (IOP) outcomes at 18 months in eyes with 

mild to moderate open-angle glaucoma or ocular hypertension

2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

, the monofocal intraocular lens (IOL) with mounted sustained-release bimatoprost implant achieved statistically and clinically significant reductions in IOP across all patient groups, with no reports of device-related adverse events.

“In the US, 5 million cataract surgeries are performed annually, with 20% occurring in patients who also have increased intraocular pressure caused by open-angle glaucoma or ocular hypertension,” said Malik Kahook, MD, co-founder of SpyGlass Pharma and a professor of ophthalmology at the University of Colorado Anschutz Medical Campus.

 “Our compelling 18-month results highlight the potential long-term benefits of the SpyGlass Drug Delivery Platform for these patients.”

A total of 23 eyes treated across 75 mcg, 150 mcg, and 300 mcg doses were included in the single-center prospective cohort study and examined at regular intervals, with a planned three-year follow-up. Investigators measured safety and efficacy using best-corrected distance visual acuity (BCDVA), IOP, and slit lamp examination.

Upon analysis, at 18 months, the BCDVA improved from a baseline range of 20/30 to 20/100 to a range of 20/16 to 20/30, while IOP was reduced from a baseline of 25.1 ± 2.5 mmHg to 14.1 ± 2.6 mmHg (

 <.0001). Investigators identified no statistically significant differences in IOP lowering across the three dosage groups, and all patients remained off topical IOP-lowering medication at the 18-month follow-up visit.

“The promising improvement in visual acuity, along with the clinically meaningful reduction in IOP, reinforce our confidence in the platform, and we look forward to sharing these data with the ophthalmic community at ASCRS,” Kahook added.

SpyGlass completed enrollment in its US Phase 1/2 study and continues to follow patients from its first-in-human trial, with plans to share long-term data soon as it works with the US Food and Drug Administration (FDA) to advance toward Phase 3 trials and commercial approval.

“We continue to see the SpyGlass Drug Delivery Platform poised to reimagine the treatment paradigm by addressing the unmet need of long-term drug delivery while also utilizing a familiar implantation technique for cataract surgeons,” said Patrick Mooney, chief executive officer of SpyGlass Pharma.

 “This promising dataset bolsters the potential for long-term durability of both visual outcomes and IOP-lowering efficacy. We look forward to providing further data updates from this ongoing study."

Robles MA, Robles PJ, Sussman G, Kahook MY, et al. Visual Outcomes of an Intraocular Lens with a Sustained-Release Bimatoprost Implant in Eyes with Open Angle Glaucoma or Ocular Hypertension. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Spyglass Pharma, Inc. Spyglass pharma presents 18-month data demonstrating compelling visual acuity results with their IOL-Mounted Innovative Drug Delivery Platform. GlobeNewswire News Room. April 24, 2025. Accessed April 25, 2025. 

https://www.globenewswire.com/news-release/2025/04/24/3067371/0/en/SpyGlass-Pharma-Presents-18-Month-Data-Demonstrating-Compelling-Visual-Acuity-Results-with-Their-IOL-mounted-Innovative-Drug-Delivery-Platform.html

Interim data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated significant improvements in vision and intraocular pressure (IOP) in patients with mild to moderate open-angle glaucoma or ocular hypertension. The study, presented at the 2025 ASCRS Annual Meeting, showed that the monofocal intraocular lens with a sustained-release bimatoprost implant achieved clinically significant IOP reductions without device-related adverse events. The study included 23 eyes across three dosage groups, with improvements in best-corrected distance visual acuity and IOP reduction maintained at 18 months.

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

SpyGlass Bimatoprost Drug Delivery Platform Improves Vision at 18 Months

Jeffrey H. Levenson, MD is the founding director and managing partner of Levenson Eye Associates.

Benefit of Clobetasol Propionate Post-Cataract Surgery, With Jeffrey Levenson, MD

Twice-daily clobetasol propionate ophthalmic suspension 0.05% for 14 days achieved rapid and sustained reduction of ocular inflammation and pain after 

, compared with placebo, in new results from two pivotal Phase 3 trials.

, clobetasol propionate ophthalmic suspension revealed quicker and greater visual acuity (VA) improvement and a similar adverse event profile to placebo, suggesting its effectiveness following ocular surgery.

“It offers the potential for a brief course of potent anti-inflammatory therapy that’s easy to comply with, just twice a day, and no need for a taper,” presenting investigator Jeffrey H. Levenson, MD, founding director and managing partner of Levenson Eye Associates, told 

. “It’s patient and doctor-friendly and might enable fewer post-operative visits, offering potential benefits over the modalities we now use.”

 approved clobetasol propionate ophthalmic suspension 0.05% for post-operative inflammation and pain following ocular surgery in March 2024, marking the first new steroid approved for eye care in 15 years.

Dual multicenter, randomized, double-masked, placebo-controlled, parallel-group studies randomized patients undergoing routine unilateral uncomplicated cataract surgery to receive clobetasol propionate ophthalmic suspension (n = 366) or placebo (n = 382) for 14 days after surgery. The primary efficacy endpoint included the proportion of patients with an anterior chamber cell (ACC) count of 0 at Days 4 to 15, with secondary endpoints including ocular pain grade at each follow-up visit.

More patients treated with clobetasol propionate ophthalmic suspension achieved an ACC of 0 at Days 8 to 15, compared with placebo (26.5% vs. 6.8%; 

 <.001), as well as a significantly higher proportion with ocular pain grade of 0 at Days 4 to 15 (71.6% vs. 27.7%; 

Those treated with clobetasol propionate ophthalmic suspension also experienced a more rapid rate of improvement and greater magnitude of improvement in the BCVA by Day 4, while significantly fewer required rescue medication (6.3% vs. 44.8%; 

 <.001). Further data showed similar increases in intraocular pressure (IOP), with only 1.4% of the clobetasol propionate ophthalmic suspension seeing increases.

Clobetasol propionate ophthalmic suspension was well-tolerated with few adverse events and similar corneal endothelial cell count (ECC) changes versus placebo.

“Patients don't mention their drops, other than to say that they're doing well and they're seeing well, and they're pleased with their surgical outcomes,” Levenson told 

. “The best comment from a patient with regards to a procedure is nothing but pleasure and seeing better.”

Levenson reports no relevant disclosures.

Levenson JH, Korenfeld MS, Silverstein SM, et al. Pivotal Phase 3 Studies of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Cataract Surgery Inflammation and Pain. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

Formosa Pharmaceuticals and AIMMAX Therapeutics receive FDA approval for Clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery. March 4, 2024. Accessed April 25, 2025. 

https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-aimmax-therapeutics-receive-fda-approval-for-clobetasol-propionate-ophthalmic-suspension-0-05-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery-302079089.html

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Surgery

The HCPLive surgery page is a resource for medical news and expert insights on invasive medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for surgery, and more.

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Prophylactic treatment with IV magnesium led to a lower risk of cisplatin-associated AKI in patients with cancer undergoing cisplatin chemotherapy.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Prophylactic IV Magnesium Linked to Lower Cisplatin-Associated AKI Risk

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Dyslipidemia

Study Indicates Lifestyle Choices are Correlated with Cardiovascular Disease Risk

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

New findings refine neuropathic pain treatment guidelines, emphasizing effective medications and the importance of personalized care for improved patient outcomes.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Updated Guidelines Needed for Neuropathic Pain Therapies

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Topline Results Released on IMG-007 Monoclonal Antibody for Alopecia Areata

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Biologic Efficacy in Psoriasis Comparable Among Older, Younger Patient Cohorts

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Real-world data show omalizumab, alone or with OIT, is effective and well-tolerated for IgE-mediated food allergy, with high response rates in adults.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Real World Data Supports Omalizumab as Monotherapy for IgE-Mediated Food Allergy

Findings suggest frequent consumption of non-skimmed milk may heighten the risk of developing MAFLD.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Non-Skimmed Milk Consumption Linked to Increased MAFLD Risk

Researchers indicated an association between the index and 365-day mortality.

Structural Heart Disease

Triglyceride Glucose Body Mass Index May Predict Coronary Heart Disease

Ten percent of effector genes identified express proteins targeted by approved drugs across disease fields.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Largest Osteoarthritis GWAS to Date Highlights Opportunities for Drug Repurposing and Novel Targets

Podcasts

In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Type 2 Diabetes

Type 1 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Latest News

Cyclosporine Solution 0.09% Boosts Outcomes in Uncontrolled Dry Eye

Implications of Gene Therapy in Retina, With Christina Y. Weng, MD

Cardiovascular Health in Youth Linked to Lower Disease Risk in Adulthood

SpyGlass Bimatoprost Drug Delivery Platform Improves Vision at 18 Months

Benefit of Clobetasol Propionate Post-Cataract Surgery, With Jeffrey Levenson, MD